Loading clinical trials...

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury | Clinical Trials | Clareo Health

COMPLETEDNA

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

NCT02010034•Children's Medical Center Dallas

View on ClinicalTrials.gov

Summary

This study is being done to determine if an investigational study drug called Omegaven can help to improve liver disease thought to be caused by Total Parenteral Nutrition (TPN). TPN is intravenous feeding (IV feeding tube) that provides patients the nutrients when they are unable to drink fluid or eat food by mouth.

Detailed Description

PAtients with direct bilirubin \>2gm/dL and short bowel syndrome are eligible for enrollment. Omegaven at 1gm/kg/day will be administered via central venous line instead of standard lipid preparations.

Eligibility

Age

0 - 10 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients must be 2 months -10 years of age
•2. Patients who are PN dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require PN for at least another 30 days
•3. Patients considered eligible for study participation must have parenteral nutrition associated liver disease (PNALD) as defined by a direct bilirubin of \>2.0mg/dL. Other causes of liver disease should be excluded. A liver biopsy is not necessary for treatment
•4. 2 consecutive direct bilirubin test results \>2.0mg/dl
•5. The patient must have failed standard therapies to prevent the progression of liver disease such as surgical treatment, cyclic TPN, avoiding overfeeding, reduction/removal of copper and manganese from TPN, advancement of enteral feeding, and use of ursodiol (Actigall)
•6. Subjects who are currently under treatment for PNALD with Compassionate Use Omegaven and have a direct Bilirubin of\< 2, but who remain TPN dependent and require continued therapy with Omegaven

Exclusion Criteria

•1. Other known causes of chronic liver disease (hepatitis C, cystic fibrosis, biliary atresia and alpha 1 anti-trypsin deficiency)
•2. Enrollment in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team)
•3. The parent, guardian, or child is unwilling to provide consent or assent
•4. Allergy to any fish product, egg protein, and/or previous allergy to Omegaven
•5. Active coagulopathies characterized by on-going bleeding or by a requirement for clotting factor replacement such as fresh frozen plasma or cryoprecipitate to maintain homeostasis
•6. Impaired lipid metabolism or severe hyperlipidemia with or without pancreatitis
•7. Unstable diabetes mellitus
•8. Stroke/embolism
•9. Collapse and shock
•10. Undefined coma status
+1 more criteria

Locations (1)

Children's Medical Center of Dallas

Dallas, Texas, United States

Key Dates

Start Date

August 1, 2013

Primary Completion Date

February 5, 2019

Completion Date

February 5, 2019

Last Updated

February 6, 2019

Enrollment

ESTIMATED participants

Conditions

Liver DiseaseImpaired Liver FunctionParenteral Nutrition Associated Liver Disease

Interventions

Omegaven

DRUG

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

NCT07480057

Chronic Liver Disease and ACLF

View study

RECRUITINGNA

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

NCT07237750

Overweight and/or ObesityMetabolic Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Inclusion Criteria

Exclusion Criteria

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

Identification of Liver Fibrosis Biomarkers

Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA